Neuronetics, Inc. (NASDAQ:STIM) Shares Sold by Kent Lake Capital LLC

Kent Lake Capital LLC lessened its stake in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 52.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,116,041 shares of the company's stock after selling 1,213,246 shares during the quarter. Neuronetics makes up about 1.3% of Kent Lake Capital LLC's portfolio, making the stock its 28th biggest position. Kent Lake Capital LLC owned approximately 3.86% of Neuronetics worth $3,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Cannell Capital LLC boosted its position in Neuronetics by 2.4% during the 3rd quarter. Cannell Capital LLC now owns 2,833,982 shares of the company's stock valued at $3,826,000 after acquiring an additional 65,240 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in Neuronetics by 1.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,417,722 shares of the company's stock valued at $4,111,000 after acquiring an additional 21,239 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Neuronetics by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,145,310 shares of the company's stock worth $3,642,000 after purchasing an additional 11,102 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of Neuronetics by 16.4% in the 2nd quarter. Silvercrest Asset Management Group LLC now owns 1,129,430 shares of the company's stock worth $2,428,000 after purchasing an additional 159,439 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Neuronetics in the 1st quarter worth $2,667,000. Institutional investors own 53.59% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on STIM shares. Piper Sandler reissued an "overweight" rating and issued a $8.00 price objective (up previously from $7.00) on shares of Neuronetics in a research report on Wednesday, March 6th. William Blair reissued a "market perform" rating on shares of Neuronetics in a research report on Tuesday, March 26th.

Insider Buying and Selling

In related news, CEO Keith J. Sullivan sold 23,958 shares of the firm's stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $2.96, for a total value of $70,915.68. Following the completion of the transaction, the chief executive officer now owns 1,434,171 shares in the company, valued at approximately $4,245,146.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Neuronetics news, CEO Keith J. Sullivan sold 23,958 shares of Neuronetics stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $2.96, for a total transaction of $70,915.68. Following the completion of the transaction, the chief executive officer now owns 1,434,171 shares in the company, valued at approximately $4,245,146.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP William Andrew Macan sold 22,377 shares of Neuronetics stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $3.16, for a total value of $70,711.32. Following the transaction, the executive vice president now owns 395,359 shares of the company's stock, valued at approximately $1,249,334.44. The disclosure for this sale can be found here. Insiders sold 160,292 shares of company stock worth $519,307 in the last 90 days. Insiders own 7.30% of the company's stock.

Neuronetics Stock Up 0.2 %

Shares of Neuronetics stock traded up $0.01 during trading on Friday, reaching $4.08. The company's stock had a trading volume of 300,416 shares, compared to its average volume of 178,389. The company has a quick ratio of 4.33, a current ratio of 4.73 and a debt-to-equity ratio of 1.73. The company has a market cap of $121.40 million, a price-to-earnings ratio of -3.81 and a beta of 2.44. Neuronetics, Inc. has a 1-year low of $1.03 and a 1-year high of $5.07. The company has a 50-day simple moving average of $3.76 and a two-hundred day simple moving average of $2.54.

Neuronetics (NASDAQ:STIM - Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. The company had revenue of $20.31 million during the quarter, compared to analyst estimates of $19.73 million. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. During the same quarter last year, the business posted ($0.30) EPS. As a group, equities analysts forecast that Neuronetics, Inc. will post -0.92 earnings per share for the current year.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.